Clinical Trial Update: Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating paclitaxel and ramucirumab with or without zanidatamab in HER2-positive advanced gastroesophageal adenocarcinoma; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Adenocarcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)
• Zanidatamab

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Gastroesophageal Adenocarcinoma | Phase 2 | Status: RECRUITING